Is Azenta (AZTA) overvalued or fairly valued?

MarketChacha shows Azenta's valuation in context — a forward P/E of about 43.9, a price-to-book of about 0.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Azenta's revenue?

Azenta reported revenue of $593.8M for FY2025, with net profit of $-55.8M, per official filings.

What is the share price of Azenta (AZTA)?

Azenta last traded at $26.94 (+1.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Azenta

AZTA · NYSE · Healthcare · United States

$26.94+1.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:33 PM

Snapshot

TickerAZTA

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees2,900

HeadquartersBurlington, United States

Market cap$1.2B

P/B0.8

Volume290.81K

Websitewww.azenta.com

Filings tracked5

About Azenta

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.0%
Institutions99.0%
Public & other0.0%

354 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.14.59%
Politan Capital Management LP10.03%
Conestoga Capital Advisors, LLC6.17%
Vanguard Portfolio Management LLC5.32%
Dimensional Fund Advisors LP4.47%
Vanguard Capital Management LLC3.97%
Massachusetts Financial Services Co.3.88%
State Street Corporation3.82%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 6.7 points over the period — profitability is trending down.

Net margin trend-2.7% → -9.4%

Margin has compressed by about 6.7 points over the period — profitability is trending down.

Return on equity-3.3%

Latest ROE of -3.3% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $157.8M · EPS 0.22

Est. earnings growth +2.9%

Next fiscal year

Rev $630.1M · EPS 0.61

Est. earnings growth +62.4%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$15.9352-wk range$41.73

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.2B

Day change

+1.3%

Fwd P/E

43.9

P/B

0.8

Beta

1.37

Revenue (FY2025)

$593.8M

Net margin

-9.4%

ROE

-3.3%

Revenue CAGR (2y)

+3.8%

EPS (FY2025)

-1.22

Net profit (FY2025)

$-55.8M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about AZTA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$593.8M	$-55.8M	-1.22	-9.4%	-3.3%
FY2024	$573.4M	$-164.9M	-3.10	-28.8%	-9.3%
FY2023	$551.5M	$-14.6M	-0.22	-2.7%	-0.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$144.8M	$-160.8M	-3.49	-111.1%
2025Q4	$148.6M	$-15.4M	-0.34	-10.4%
2025Q3	$159.2M	$50.9M	1.11	32.0%
2025Q2	$143.9M	$-48.0M	-1.05	-33.4%
2025Q1	$143.3M	$-47.7M	-1.04	-33.3%
2024Q4	$147.4M	$-11.0M	-0.25	-7.5%
2024Q3	$150.6M	$-6.6M	-0.14	-4.4%
2024Q2	$144.3M	$-6.6M	-0.12	-4.5%
2024Q1	$136.4M	$-137.4M	-2.48	-100.8%
2023Q4	$142.2M	$-14.3M	-0.25	-10.0%
2023Q2	$165.9M	$-1.5M	-0.02	-0.9%
2023Q1	$148.4M	$-4.9M	-0.07	-3.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Material agreement, Completion of acquisition/disposition, Reg FD disclosure, Exhibits
SEC7/8/2026material
10-Q filing
SEC5/8/2026
8-K — Results of operations, Exhibits
SEC5/5/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC4/7/2026material
8-K — Other events
SEC4/2/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.